Boston Scientific today shared study data supporting the use of its Eluvia drug-eluting stent for treating PAD. The company shared multiple new clinical data sets at Charing Cross 2025 in London today. Findings reinforced the growing body of evidence supporting the Eluvia stent for treating peripheral artery disease (PAD) — particularly in the … [Read more...] about Data backs Boston Scientific drug-eluting stent
Boston Scientific
Boston Scientific Farapulse PFA system shows superiority in head-to-head study with Medtronic cryoablation system
Boston Scientific announced new study findings demonstrating the superiority of its Farapulse pulsed field ablation (PFA) system. Data published in the New England Journal of Medicine showed Farapulse's superiority in reducing atrial arrhythmia (AA) recurrence or treating symptomatic, drug-refractory paroxysmal atrial fibrillation (PAF) compared … [Read more...] about Boston Scientific Farapulse PFA system shows superiority in head-to-head study with Medtronic cryoablation system
Boston Scientific to acquire renal denervation company SoniVie
Boston Scientific (NYSE:BSX) announced today that it agreed to acquire intravascular ultrasound system developer SoniVie. Marlborough, Massachusetts-based Boston Scientific is a strategic investor in SoniVie, holding about a 10% equity stake. With this stake, the transaction features an upfront payment of approximately $360 million for the 90% … [Read more...] about Boston Scientific to acquire renal denervation company SoniVie
Boston Scientific reports first cases with next-gen Faraflex catheter
Boston Scientific today announced the completion of the first-ever cases with its Faraflex mapping and pulsed field ablation (PFA) catheter. This latest technology marks another milestone for the Farapulse PFA portfolio. Boston Scientific initially won FDA approval for Farapulse in January 2024 and has since reported a number of significant … [Read more...] about Boston Scientific reports first cases with next-gen Faraflex catheter
Boston Scientific wins CE mark for Farapulse Nav mapping tech
Boston Scientific announced today that it received CE mark for its navigation-enabled Farawave Nav ablation catheter and Faraview software. Farawave Nav and the Faraview software make up part of the company’s Farapulse pulsed field ablation (PFA) system. Boston Scientific initially won FDA approval for Farapulse in January 2024. In doing so, it … [Read more...] about Boston Scientific wins CE mark for Farapulse Nav mapping tech
Boston Scientific makes IVL play with Bolt Medical acquisition
Boston Scientific (NYSE: BSX) announced today that it agreed to acquire intravascular lithotripsy (IVL) platform developer Bolt Medical. On a 100% basis — before considering an existing equity stake and other adjustments — the deal is valued at $600 million upfront with up to an additional $300 million upon achievement of certain regulatory … [Read more...] about Boston Scientific makes IVL play with Bolt Medical acquisition
Boston Scientific updates instructions for cryoablation catheters after reported deaths
The FDA issued a notice alerting customers to updates made by Boston Scientific to its PolarX cryoablation catheters. This recall involves updating instructions for use (IFU), not removing devices from the market. The FDA identified it as the most serious type of recall, though, as it may cause serious injury or death. Boston Scientific … [Read more...] about Boston Scientific updates instructions for cryoablation catheters after reported deaths
Boston Scientific to acquire hepatic artery infusion pump maker Intera Oncology
Boston Scientific (NYSE:BSX) announced today that it agreed to acquire infusion pump maker Intera Oncology for an undisclosed amount. Intera Oncology develops the Intera 3000 hepatic artery infusion pump and floxuridine, a chemotherapy drug. Both hold FDA approval. The pump administers hepatic artery infusion (HAI) therapy to treat tumors in the … [Read more...] about Boston Scientific to acquire hepatic artery infusion pump maker Intera Oncology
Boston Scientific resumes study of pulse field ablation as first-line AFib therapy
Boston Scientific (NYSE: BSX) is resuming its “Avant Guard” study of pulse field ablation as a first-line therapy for persistent atrial fibrillation (AFib). The device developer paused the trial last month, with CEO Mike Mahoney citing the need to “assess a few unanticipated observations.” Boston Scientific said it did not halt the trial due to … [Read more...] about Boston Scientific resumes study of pulse field ablation as first-line AFib therapy
Boston Scientific to acquire Cortex and its cardiac mapping tech
Boston Scientific (NYSE: BSX) announced today that it will purchase Ajax Health's Cortex and its FDA-cleared OptiMap system to guide physicians performing ablation procedures to treat AFib Financial terms of the deal were not disclosed. Boston Scientific expects to complete the transaction in the first half of 2025, subject to customary closing … [Read more...] about Boston Scientific to acquire Cortex and its cardiac mapping tech
